Yesin Mahmut, Karakoyun Süleyman, Kalçık Macit, Gürsoy Mustafa Ozan, Gündüz Sabahattin, Astarcıoğlu Mehmet Ali, Bayam Emrah, Cerşit Sinan, Güner Ahmet, Özkan Mehmet
Kars Harakani State Hospital, Department of Cardiology, Kars, Turkey.
Kafkas University Medical School, Department of Cardiology, Kars, Turkey.
Am J Cardiol. 2018 Aug 15;122(4):638-644. doi: 10.1016/j.amjcard.2018.04.045. Epub 2018 May 11.
Coronary thromboembolism (CE) is a rare cause of prosthetic valve derived complications. This study investigates the diagnosis and treatment strategies for non-ST elevation acute coronary syndrome (NSTEACS) in patients with prosthetic heart valves. Forty-eight NSTEACS patients with prosthetic heart valves (mitral:27; aortic:14; mitral+aortic:7) were included in this study. All patients underwent transthoracic and transesophageal echocardiographic examination and coronary angiography. Normal coronary angiographic findings, or visible trombus in one of the coronary arteries, international normalized ratio <2, concomitant prosthetic valve thrombosis (PVT) and absence of multivessel atherosclerotic disease favored CE rather than atherothrombosis. Thrombolytic therapy (TT) with low-dose slow-infusion of tissue type plasminogen activator was used in patients with suspected CE and/or PVT. Coronary angiography demonstrated normal coronary arteries in 26 patients, CE in 16 patients and coronary atherosclerosis in 6 patients. Transesophageal echocardiography revealed obstructive PVT in 9 and nonobstructive PVT in 28 patients whereas 11 patients had normally functioning prostheses. TT was administered to 24 patients with PVT and/or CE. In these patients, TT was successful in 19 patients, partially successful in 4 patients and failed in 1 patient. In conclusion, NSTEACS in patients with prosthetic heart valves is more likely to be associated with PVT derived CE rather than atherosclerosis. TT with low-dose slow infusion of type plasminogen activator has proved its efficacy and safety in patients with CE and/or PVT.
冠状动脉血栓栓塞(CE)是人工瓣膜衍生并发症的罕见原因。本研究调查人工心脏瓣膜患者非ST段抬高急性冠状动脉综合征(NSTEACS)的诊断和治疗策略。本研究纳入了48例人工心脏瓣膜的NSTEACS患者(二尖瓣:27例;主动脉瓣:14例;二尖瓣+主动脉瓣:7例)。所有患者均接受了经胸和经食管超声心动图检查及冠状动脉造影。冠状动脉造影结果正常,或冠状动脉之一可见血栓,国际标准化比值<2,合并人工瓣膜血栓形成(PVT)且无多支血管动脉粥样硬化疾病,提示为CE而非动脉粥样硬化血栓形成。对于疑似CE和/或PVT的患者,采用低剂量缓慢输注组织型纤溶酶原激活剂的溶栓治疗(TT)。冠状动脉造影显示26例患者冠状动脉正常,16例患者为CE,6例患者为冠状动脉粥样硬化。经食管超声心动图显示9例患者存在阻塞性PVT,28例患者存在非阻塞性PVT,而11例患者人工瓣膜功能正常。24例PVT和/或CE患者接受了TT治疗。在这些患者中,TT治疗成功19例,部分成功4例,失败1例。总之,人工心脏瓣膜患者的NSTEACS更可能与PVT衍生的CE相关,而非动脉粥样硬化。低剂量缓慢输注纤溶酶原激活剂的TT已证明其在CE和/或PVT患者中的有效性和安全性。